Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 | P11802 | 3/20 | 0.32 |
| ▸ | CCND1 | P24385 | 3/20 | 0.32 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.32 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.32 |
| ▸ | CA12 | O43570 | 2/20 | 0.30 |
| ▸ | CA9 | Q16790 | 2/20 | 0.30 |
| ▸ | BRD4 | O60885 | 1/20 | 0.30 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.30 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.30 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3849038 | 0.71 | CA12 (0.34) | CDK4CCND1CYP2A6ALOX12CA12 | |
| SCHEMBL650735 | 0.71 | NOS2 (0.34) | CDK4CCND1CYP2A6ALOX12CA12 | |
| SCHEMBL137023 | 0.71 | CA12 (0.39) | CDK4CCND1CYP2A6ALOX12CA12 | |
| SCHEMBL2073630 | 0.71 | CDK4 (0.32) | CDK4CCND1CYP2A6ALOX12CA12 | |
| SCHEMBL127255 | 0.71 | DAO (0.35) | CDK4CCND1CYP2A6ALOX12CA12 | |
| SCHEMBL2073401 | 0.71 | CDK4 (0.32) | CDK4CCND1CYP2A6ALOX12CA12 | |
| SCHEMBL718221 | 0.68 | KDM4E (0.37) | CDK4CCND1ALDH1A1 | |
| SCHEMBL15271285 | 0.67 | RECQL (0.35) | CDK4CCND1 | |
| SCHEMBL18838526 | 0.67 | — | — | |
| SCHEMBL4724354 | 0.67 | SLC6A2 (0.35) | CA12CA9BRD4BRPF1KAT2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150167049-A1 | DETECTION AND DISTINCTION OF TRICHOMONAS AND CANDIDA | WANG ZEYU (CN) | 2015-06-18 | — | — | US | claimed |
| US-20120034637-A1 | DETECTION OF TRICHOMONAS AND CANDIDA | Autobio Diagnostics Co., Ltd. (CN) | 2012-02-09 | — | — | US | claimed |
| EP-2407549-A1 | DETECTION OF TRICHOMONAS AND CANDIDA | Autobio Diagnostics Co., Ltd. (CN) | 2012-01-18 | — | — | EP | claimed |
| CN-118234731-A | RAS inhibitors | 锐新医药公司 | 2024-06-21 | — | — | CN | disclosed |
| CN-117979966-A | Treatment of cancer using SOS1 inhibitors and RAS inhibitors | 锐新医药公司 | 2024-05-03 | — | — | CN | disclosed |
| WO-2024081363-A1 | COMPOSITION COMPRISING A FIRST RAS INHIBITOR, SECOND RAS INHIBITOR AND A SHP2 INHIBITOR FOR USE IN THE TREATMENT OF CANCER | Revolution Medicines, Inc. (US) | 2024-04-18 | — | — | WO | disclosed |
| EP-4346898-A1 | METHODS FOR INHIBITING RAS | Revolution Medicines, Inc. (US) | 2024-04-10 | — | — | EP | disclosed |
| US-11952352-B2 | Ras inhibitors | Revolution Medicines, Inc. (US) | 2024-04-09 | — | — | US | disclosed |
| US-20240108630-A1 | METHODS FOR INHIBITING RAS | Revolution Medicines, Inc. | 2024-04-04 | — | — | US | disclosed |
| CN-117715658-A | Method for inhibiting RAS | 锐新医药公司 | 2024-03-15 | — | — | CN | disclosed |
| EP-4334321-A1 | RAS INHIBITORS | Revolution Medicines, Inc. (US) | 2024-03-13 | — | — | EP | disclosed |
| EP-1976833-A2 | HETEROCYCLE SUBSTITUTED AMIDE AND SULFUR AMIDE DERIVATIVES AS HISTONE DEACETYLASE (HDAC) INHIBITORS | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI S.P.A. (IT) | 2008-10-08 | — | — | EP | disclosed |
| EP-1828171-A2 | HETEROCYCLE DERIVATIVES AS HISTONE DEACETYLASE (HDAC) INHIBITORS | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI S.P.A. (IT) | 2007-09-05 | — | — | EP | disclosed |
| WO-2007052073-A2 | HETEROCYCLE SUBSTITUTED AMIDE AND SULFUR AMIDE DERIVATIVES AS HISTONE DEACETYLASE (HDAC) INHIBITORS | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) | 2007-05-10 | — | — | WO | disclosed |
| WO-2006061638-A2 | HETEROCYCLE DERIVATIVES AS HISTONE DEACETYLASE (HDAC) INHIBITORS | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P ANGELETTI SPA (IT) | 2006-06-15 | — | — | WO | disclosed |
| EP-1341766-B1 | IMIDAZOLONE DERIVATIVES FOR THE TREATMENT OF VIRAL DISEASES | HOFFMANN LA ROCHE (CH) | 2005-10-26 | — | — | EP | disclosed |
| EP-1341766-A1 | IMIDAZOLONE DERIVATIVES FOR THE TREATMENT OF VIRAL DISEASES | F. HOFFMANN-LA ROCHE AG (CH) | 2003-09-10 | — | — | EP | disclosed |
| US-6518293-B2 | Inhibitors of the human immunodeficiency virus reverse transcriptase enzyme which is involved in viral replication. | HOFFMANN-LA ROCHE INC. | 2003-02-11 | — | — | US | disclosed |
| US-20020107272-A1 | Anti-HIV imidazolone derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2002-08-08 | — | — | US | disclosed |
| WO-2002042279-A1 | IMIDAZOLONE DERIVATIVES FOR THE TREATMENT OF VIRAL DISEASES | F. HOFFMANN-LA ROCHE AG (CH) | 2002-05-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020107272-A1 | Anti-HIV imidazolone derivatives | EIF2AK2, IMPDH1, POLR2E | CDK4 80/4885CCND1 622/4885CYP2A6 1283/4885 |
| US-11952352-B2 | Ras inhibitors | KRAS, NRAS, HRAS | CDK4 103/4885CCND1 872/4885CYP2A6 3875/4885 |
| US-20240108630-A1 | METHODS FOR INHIBITING RAS | KRAS, HRAS, NRAS | CDK4 1385/4885CCND1 3585/4885CYP2A6 4766/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.